drugset / Trial / NCT06642545
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Evaluating the Efficacy of Disitamab Vedotin in Combination with RC148 Compared to Albumin-bound Paclitaxone Monotherapy or in Combination with Toripalimab for Subjects with HR-negative, HER2-low Expressing Unresectable Locally Advanced or Metastatic Breast Cancer
Timeline
- Start
- 2025-02-10
- Primary completion
- 2026-10-01
- Completion
- 2027-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Disitamab Vedotin | Monoclonal antibody | 2 mg/kg | Intravenous |
| Comparator | Paclitaxone | Unknown | 125 mg/m2 | Intravenous |
| Subject | RC148 | Unknown | 20 mg/kg | Intravenous |
| Comparator | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |